Rise Nano Optics to Commence Trading on the Canadian Securities Exchange Under the Symbol "EYE", Today, March 12, 2026
Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Rise Nano Optics Ltd. (CSE: EYE) ("Rise" or the "Company") is pleased to announce that it has received approval to list its common shares (the "Common Shares") on the Canadian Securities Exchange (the "CSE"). Trading is expected to commence on the CSE under the symbol "EYE" at the open of markets on March 12, 2026. Inas Said, CEO of Rise commented, "Listing publicly represents an important milestone for Rise Nano Optics and...
2026-03-12 7:00 AM EDT
Rise Health Nano Optics Granted Third U.S. Patent for Breakthrough Nano-Optic Technology Advancing Preventative Vision Care
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health technology innovator specializing in nano-optic solutions that effectively block wavelengths of light linked to vision stress and degenerative eye disease, is pleased to announce the granting of its third U.S. technology patent – U.S. Patent No. 12,383,955 (B2) – further strengthening its proprietary leadership position in advanced eye-protection nanomaterials....
2025-11-04 7:00 AM EST
Rise Health Nano Optics Achieves FDA Clearance Milestone Following Successful Biocompatibility Testing for EYEGUARD Lenses
Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Rise Health Nano Optics Inc. ("Rise" or the "Company"), a health-tech innovator specializing in advanced, preventative optical solutions, is pleased to announce a major milestone in its regulatory pathway toward global market entry. Following a formal review meeting with the U.S. Food and Drug Administration ("FDA") on April 3, 2025, the FDA confirmed: Classification Agreement: EYEGUARD™ lenses are confirmed as Class I,...
2025-09-17 4:00 AM EDT